These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33743527)

  • 41. Quality of life in thyroid eye disease: impact of quality of care.
    Estcourt S; Quinn AG; Vaidya B
    Eur J Endocrinol; 2011 May; 164(5):649-55. PubMed ID: 21367964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Basedow's ophthalmopathy].
    Raynaud L; Benois A; Lafond P
    Rev Prat; 2008 May; 58(10):1060. PubMed ID: 18652402
    [No Abstract]   [Full Text] [Related]  

  • 43. The diagnosis and treatment of thyroid-associated ophthalmopathy.
    Gould DJ; Roth FS; Soparkar CN
    Aesthetic Plast Surg; 2012 Jun; 36(3):638-48. PubMed ID: 22083413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The evaluation and treatment of graves ophthalmopathy.
    Stan MN; Garrity JA; Bahn RS
    Med Clin North Am; 2012 Mar; 96(2):311-28. PubMed ID: 22443978
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Thyroid ophthalmopathy at the time of European Group On Graves Orbitopathy (EUGOGO)].
    Sadoul JL
    Presse Med; 2011 Dec; 40(12 Pt 1):1163-73. PubMed ID: 22119334
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal management of Graves orbitopathy: a multidisciplinary approach.
    Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
    Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Management of Graves' orbitopathy. Comments on the EUGOGO consensus statement].
    Bednarczuk T; Bar-Andziak E; Hubalewska-Dydejczyk A; Waligórska A; Górska M; Myśliwiec J; Jarzab B; Karczmarzyk R; Zawadzka A; Garmol D; Kecik D; Królicki L; Plazińska MT; Krzeski A; Krzyzanowska-Swiniarska B; Lewiński A; Milewicz A; Daroszewski J; Placzkiewicz-Jankowska E; Pilarska K; Skórski M; Wiechno W; Sowiński J; Syrenicz A; Szafilk J; Wanyura H; Zgliczński W; Jastrzebska H; Nauman J
    Endokrynol Pol; 2009; 60(4):312-30. PubMed ID: 19753546
    [No Abstract]   [Full Text] [Related]  

  • 48. [Thyroid associated orbitopathy: from diagnosis to treatment].
    Hamédani M; Obéric A
    Rev Med Suisse; 2013 Jan; 9(368):66-71. PubMed ID: 23367708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pediatric thyroid-associated orbitopathy: the Children's Hospital of Philadelphia experience and literature review.
    Goldstein SM; Katowitz WR; Moshang T; Katowitz JA
    Thyroid; 2008 Sep; 18(9):997-9. PubMed ID: 18713025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Graves' Orbitopathy].
    Eckstein A; Esser J; Mattheis S; Berchner-Pfannschmidt U
    Klin Monbl Augenheilkd; 2016 Dec; 233(12):1385-1407. PubMed ID: 27871109
    [No Abstract]   [Full Text] [Related]  

  • 52. [Endocrine orbitopathy: the present view of a clinical endocrinologist].
    Jiskra J
    Vnitr Lek; 2017; 63(10):690-696. PubMed ID: 29127744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nomenclature: thyroid-associated orbitopathy, Graves ophthalmopathy, or thyroid eye disease?
    Ing EB; Madjedi K; Hurwitz JJ; Nijhawan N; Oestreicher J; Torun N
    Can J Ophthalmol; 2021 Feb; 56(1):e22-e24. PubMed ID: 32702305
    [No Abstract]   [Full Text] [Related]  

  • 54. [Graves' ophthalmopathy].
    Caballero Mora FJ; Martos Moreno GA; Gutiérrez Partida B; Argente J
    An Pediatr (Barc); 2012 Nov; 77(5):355-6. PubMed ID: 22682548
    [No Abstract]   [Full Text] [Related]  

  • 55. Management of patients with Graves' orbitopathy: initial assessment, management outside specialized centres and referral pathways.
    Orgiazzi J
    Clin Endocrinol (Oxf); 2016 May; 84(5):662-3. PubMed ID: 26866718
    [No Abstract]   [Full Text] [Related]  

  • 56. Euthyroid Graves' ophthalmopathy with negative autoantibodies.
    Cakir M
    J Natl Med Assoc; 2005 Nov; 97(11):1547-9. PubMed ID: 16334503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association.
    Burch HB; Perros P; Bednarczuk T; Cooper DS; Dolman PJ; Leung AM; Mombaerts I; Salvi M; Stan MN
    Thyroid; 2022 Dec; 32(12):1439-1470. PubMed ID: 36480280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pathogenetic, clinical and therapeutical features of ophthalmologic involvement in Basedow's disease].
    Verraz R
    Arch Sci Med (Torino); 1969 Sep; 126(9):699-704. PubMed ID: 17340828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
    Edmunds MR; Boelaert K
    Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Orbital lymphoma associated with Graves' disease: A case report.
    Hajduković Z; Kuzmić-Janković S; Kljaković-Avramović T; Sekulović L; Tukić L
    Vojnosanit Pregl; 2014 May; 71(5):510-4. PubMed ID: 26137719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.